| Ryan Karmouta, MD, MBA | |
|
31 Stiles Rd Ste 2100, Salem, NH 03079-3035 | |
| (603) 942-2020 | |
| (603) 288-1722 |
| Full Name | Ryan Karmouta |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Location | 31 Stiles Rd Ste 2100, Salem, New Hampshire |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316441066 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | MD26935 (Maine) | Secondary |
| 207N00000X | Dermatology | 22327 (New Hampshire) | Primary |
| Entity Name | Optima Dermatology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831187764 PECOS PAC ID: 3971561648 Enrollment ID: O20220329002691 |
News Archive
While falls are a common cause of injury, particularly in older, hospitalized patients, some may not be as preventable as once thought. According to a new literature review published in the Journal of the American Academy of Orthopaedic Surgeons, many of the risks that frequently cause falls are not adequately addressed with the fall prevention initiatives used in healthcare facilities.
The theory that depression is caused by a chemical imbalance is often presented in the media as fact even though there is little scientific evidence to support it, according to a new study co-authored by a Florida State University visiting lecturer.
UC San Francisco researchers have engineered a molecular "on switch" that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe, sometimes deadly side effects that have been a significant hurdle to advancing T cell-based treatments.
Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform. CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Karmouta, MD, MBA 111 New Hampshire Ave Ste 2, Portsmouth, NH 03801-2864 Ph: (802) 909-2053 | Ryan Karmouta, MD, MBA 31 Stiles Rd Ste 2100, Salem, NH 03079-3035 Ph: (603) 942-2020 |
News Archive
While falls are a common cause of injury, particularly in older, hospitalized patients, some may not be as preventable as once thought. According to a new literature review published in the Journal of the American Academy of Orthopaedic Surgeons, many of the risks that frequently cause falls are not adequately addressed with the fall prevention initiatives used in healthcare facilities.
The theory that depression is caused by a chemical imbalance is often presented in the media as fact even though there is little scientific evidence to support it, according to a new study co-authored by a Florida State University visiting lecturer.
UC San Francisco researchers have engineered a molecular "on switch" that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe, sometimes deadly side effects that have been a significant hurdle to advancing T cell-based treatments.
Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform. CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.
› Verified 2 days ago